DSpace

Digital.CSIC > Biología y Biomedicina > Centro Nacional de Biotecnología (CNB) > (CNB) Artículos >

Share

EndNote

Impact

Links

Closed Access item Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1(BX08) gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B

Authors:Gómez, Carmen E.
Nájera García, José Luis
Pérez Jiménez, Eva
Jiménez, Victoria
Wagner, Ralf
Graf, Marcus
Frachette, Marie-Joelle
Liljeström, Peter
Pantaleo, Giuseppe
Esteban, Mariano
Keywords:HIV/AIDS, Clade B vaccine, Poxvirus vectors, MVA, NYVAC, Immune response, Mouse models
Issue Date:16-Oct-2006
Publisher:Elsevier
Citation:Vaccine 25(15): 2863-2885 (2007)
Abstract:In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Pol-Nef antigens of clade B (referred as MVA-B and NYVAC-B). In infected human HeLa cells, gp120 is released from cells and GPN is produced as a polyprotein; NYVAC-B induces severe apoptosis but not MVA-B. The two poxvirus vectors showed genetic stability of the inserts. In BALB/c and in transgenic HHD mice for human HLA-A2 class I, both vectors are efficient immunogens and induced broad cellular immune responses against peptides represented in the four HIV-1 antigens. Some differences were observed in the magnitude and breadth of the immune response in the mouse models. In DNA prime/poxvirus boost protocols, the strongest immune response, as measured by fresh IFN-γ and IL-2 ELISPOT, was obtained in BALB/c mice boosted with NYVAC-B, while in HHD mice there were no differences between the poxvirus vectors. When the prime/boost was performed with homologous or with combination of poxvirus vectors, the protocols MVA-B/MVA-B and NYVAC-B/NYVAC-B, or the combination NYVAC-B/MVA-B gave the most consistent broader immune response in both mouse models, although the magnitude of the overall response was higher for the DNA-B/poxvirus-B regime. All of the immunization protocols induced some humoral response against the gp160 protein from HIV-1 clone LAV. Our findings indicate that MVA-B and NYVAC-B meet the criteria to be potentially useful vaccine candidates against HIV/AIDS.
Description:23 pages, 8 figures.-- PMID: 17113200 [PubMed].-- Includes Appendix A: DNA sequence of MVA-B in the TK viral locus.-- Printed version published on Apr 12, 2007.
Publisher version (URL):http://dx.doi.org/10.1016/j.vaccine.2006.09.090
URI:http://hdl.handle.net/10261/8801
ISSN:0264-410X
???metadata.dc.identifier.doi???:10.1016/j.vaccine.2006.09.090
Appears in Collections:(CNB) Artículos

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.